News

We'd like to introduce you to Meg, who started volunteering at The Clatterbridge Cancer Centre this year.

International Clinical Trials Day (May 20) celebrates innovations that improve medical care and a new technique is targeting hard to reach tumours at The Clatterbridge Cancer Centre.

Clatterbridge’s research trials teams rose to the challenge over the past 12 months to continue their groundbreaking work, despite Coronavirus threatening to derail it.

Working mum swapped a career in retail for a role in research into COVID-19.

A drug called Osimertinib has just been approved for routine use for people with early-stage EGFR-driven lung cancers in a landmark UK agreement. Dr Carles Escriu, a Consultant Medical Oncologist specialising in thoracic cancers at The Clatterbridge Cancer Centre NHS Foundation Trust, explains why this matters and how Osimertinib could benefit people with early-stage lung cancer linked to EGFR gene mutation.

Information about how people who have/had blood cancer, their relatives/carers and others with experience of blood cancer services can have their say on proposals aimed at further enhancing the care people receive at Aintree University Hospital and Clatterbridge Cancer Centre - Liverpool.

38-year-old Rob Gore’s diagnosis is very rare for a man of his age.

​When Debbie Roberts’ cancer treatment ended, it was just the start of her involvement in finding new ways to give hope to others with the disease. Debbie is living with ovarian cancer that is now in check and is part of a research trial designed to improve outcomes for other women with an advanced form of the disease.

Paula, who is being treated by The Clatterbridge Cancer Centre, has become one of the first people in England to benefit from a new 5-minute breast cancer treatment being rolled out across the NHS. Phesgo combines trastuzumab and pertuzumab into a single injection for HER2-positive breast cancers.